Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus

Guo, Hui; Ma, Jiangtao; Mao, Yan; Hu, Ziwei; Lin, Ying; Yu, Feng; Wang, Wei; Liu, Yaling

doi:10.3389/fbioe.2023.1180302

Cited by 3 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These properties have led to PLGA being approved by the FDA for parenteral administration and therefore make it an attractive candidate for nucleic acid delivery 115 . The SA (sialic acid)‐poly (D, L‐lactide‐co‐glycolide) (SA‐PLGA) nano delivery system was used to deliver antagomiR‐7 to splenic B cells 116 . This treatment led to a reduction in B‐cell activity and improvement in lupus nephritis.…”

Section: In Vivo Delivery Vehiclesmentioning

confidence: 99%

“…115 The SA (sialic acid)-poly (D, L-lactide-co-glycolide) (SA-PLGA) nano delivery system was used to deliver antagomiR-7 to splenic B cells. 116 This treatment led to a reduction in B-cell activity and improvement in lupus nephritis. This study demonstrated the therapeutic potential of polymeric nanoparticles in targeting specific immune-cell subsets in the context of autoimmune disease.…”

Section: Polymersmentioning

confidence: 99%

See 1 more Smart Citation

InflammamiRs in focus: Delivery strategies and therapeutic approaches

Akkaya‐Ulum,

Sen,

Akbaba

et al. 2024

The FASEB Journal

View full text Add to dashboard Cite

AbstractmicroRNAs (miRNAs) are small non‐protein‐coding RNAs which are essential regulators of host genome expression at the post‐transcriptional level. There is evidence of dysregulated miRNA expression patterns in a wide variety of diseases, such as autoimmune and inflammatory conditions. These miRNAs have been termed “inflammamiRs.” When working with miRNAs, the method followed, the approach to treat or diagnosis, and the selected biological material are very crucial. Demonstration of the role of miRNAs in particular disease phenotypes facilitates their evaluation as potential and effective therapeutic tools. A growing number of reports suggest the significant utility of miRNAs and other small RNA drugs in clinical medicine. Most miRNAs seem promising therapeutic options, but some features associated with miRNA therapy like off‐target effect, effective dosage, or differential delivery methods, mainly caused by the short target's sequence, make miRNA therapies challenging. In this review, we aim to discuss some of the inflammamiRs in diseases associated with inflammatory pathways and the challenge of identifying the most potent therapeutic candidates and provide a perspective on achieving safe and targeted delivery of miRNA therapeutics. We also discuss the status of inflammamiRs in clinical trials.

show abstract

Section: In Vivo Delivery Vehiclesmentioning

confidence: 99%

Section: Polymersmentioning

confidence: 99%

InflammamiRs in focus: Delivery strategies and therapeutic approaches

Akkaya‐Ulum,

Sen,

Akbaba

et al. 2024

The FASEB Journal

View full text Add to dashboard Cite

show abstract

“…The therapy reduces immunological abnormalities, restores normal splenic B cell subtypes, and inhibits B cell activation. 220 The delivery of miRNAs via nanoplatforms in inflammatory diseases such as IBD could show promising responses to TNF-α expression. Recently, Louiselle and colleagues, conjugated cerium oxide nanoparticle (CNP)/miRNA-146a embedded chitosan-based gel to target the unregulated inflammatory responses witnessed in IBD/colitis.…”

Section: Mirna Based Targeted Therapeutics In Adsmentioning

confidence: 99%

“…The research findings indicate that SA‐PLGA@antagomiR‐7 possesses favorable biocompatibility and protects antagomiR‐7 against degradation, hence prolonging the presence of the miRNA in the circulatory system in vivo. The therapy reduces immunological abnormalities, restores normal splenic B cell subtypes, and inhibits B cell activation 220 …”

Section: Mirna Based Targeted Therapeutics In Adsmentioning

confidence: 99%

Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases: A comprehensive review

Nag,

Mitra,

Tripathi

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundAutoimmune diseases (AD) are severe pathophysiological ailments that are stimulated by an exaggerated immunogenic response towards self‐antigens, which can cause systemic or site‐specific organ damage. An array of complex genetic and epigenetic facets majorly contributes to the progression of AD, thus providing significant insight into the regulatory mechanism of microRNA (miRNA). miRNAs are short, non‐coding RNAs that have been identified as essential contributors to the post‐transcriptional regulation of host genome expression and as crucial regulators of a myriad of biological processes such as immune homeostasis, T helper cell differentiation, central and peripheral tolerance, and immune cell development.AimsThis article tends to deliberate and conceptualize the brief pathogenesis and pertinent epigenetic regulatory mechanism as well as miRNA networks majorly affecting five different ADs namely rheumatoid arthritis (RA), type 1 diabetes, multiple sclerosis (MS), systemic lupus erythematosus (SLE) and inflammatory bowel disorder (IBD) thereby providing novel miRNA‐based theranostic interventions.Results & DiscussionPertaining to the differential expression of miRNA attributed in target tissues and cellular bodies of innate and adaptive immunity, a paradigm of scientific expeditions suggests an optimistic correlation between immunogenic dysfunction and miRNA alterations.ConclusionTherefore, it is not astonishing that dysregulations in miRNA expression patterns are now recognized in a wide spectrum of disorders, establishing themselves as potential biomarkers and therapeutic targets. Owing to its theranostic potencies, miRNA targets have been widely utilized in the development of biosensors and other therapeutic molecules originating from the same.

show abstract

Reduced miR-99a-3p levels in systemic lupus erythematosus may promote B cell proliferation via NCAPG and the PI3K/AKT signaling pathway

Zhu,

Zhou,

Yang

et al. 2024

Lupus

View full text Add to dashboard Cite

Background Systemic lupus erythematosus is an immunologically dysregulated disease characterized by the presence of multiple autoantibodies. In SLE, B lymphocytes contribute to the dysregulated production of autoantibodies and cytokines. Recently, we discovered that miR-99a-3p binds to both EIF4EBP1 and NCAPG mRNA and that lowering miR-99a-3p can promote B cell autophagy in SLE by increasing EIF4EBP1 expression. However, the functions of miR-99a-3p and NCAPG in SLE have not been extensively investigated. Objective This work aims to evaluate the levels of miR-99a-3p and NCAPG expression in SLE B cells and to determine whether the aberrant expression of miR-99a-3p and NCAPG contributes to the pathological mechanisms in SLE. Methods B lymphocytes were obtained through immunomagnetic negative selection. Using RT-qPCR, miR-99a-3p and NCAPG mRNA expressions in B lymphocytes and in the BALL-1 cell line were measured. To determine the relative abundance of NCAPG, PI3K, p-PI3K, AKT, and p-AKT, we normalize them to the level of β-actin using Western blotting. Evaluation of miR-99a-3p and NCAPG’s impact on cell proliferation was done utilizing CCK-8 assay. Using flow cytometry, the cell cycle and apoptosis were both measured. Results Comparing SLE B cells to healthy controls, miR-99a-3p expression was significantly downregulated. Additionally, it was observed that SLE B cells had significantly higher NCAPG mRNA expression. Blocking miR-99a-3p expression in BALL-1 cells with an antagomir elevated NCAPG expression, facilitated PI3K/AKT pathway activation, improved cell proliferation, raised the fraction of S-phase cells, and prevented cell apoptosis. The opposite effects of upregulated miR-99a-3p levels on BALL-1 cells were observed by using an agomir. Furthermore, the effect of decreased miR-99a-3p expression on cell proliferation was partially mediated by elevating NCAPG levels and activating the PI3K/AKT pathway. Conclusion Our research indicates that lower miR-99a-3p expression in SLE B cells appears to boost B cell number via the NCAPG and PI3K/AKT pathways.

show abstract

Delivery of AntagomiR-7 through polymer nanoparticles for assisting B Cell to alleviate systemic lupus erythematosus

Cited by 3 publications

References 53 publications

InflammamiRs in focus: Delivery strategies and therapeutic approaches

InflammamiRs in focus: Delivery strategies and therapeutic approaches

Exploring the theranostic potentials of miRNA and epigenetic networks in autoimmune diseases: A comprehensive review

Reduced miR-99a-3p levels in systemic lupus erythematosus may promote B cell proliferation via NCAPG and the PI3K/AKT signaling pathway

Contact Info

Product

Resources

About